<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="pt-BR">
		<id>http://www.infosus.saude.sc.gov.br/index.php?action=history&amp;feed=atom&amp;title=Ribavirina</id>
		<title>Ribavirina - Histórico de revisão</title>
		<link rel="self" type="application/atom+xml" href="http://www.infosus.saude.sc.gov.br/index.php?action=history&amp;feed=atom&amp;title=Ribavirina"/>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;action=history"/>
		<updated>2026-10-12T07:23:40Z</updated>
		<subtitle>Histórico de revisões para esta página neste wiki</subtitle>
		<generator>MediaWiki 1.28.0</generator>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=76608&amp;oldid=prev</id>
		<title>Anonimo: /* Alternativas terapêuticas disponíveis no SUS */</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=76608&amp;oldid=prev"/>
				<updated>2026-10-06T21:07:37Z</updated>
		
		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Alternativas terapêuticas disponíveis no SUS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 21h07min de 6 de outubro de 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l41&quot; &gt;Linha 41:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 41:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Alternativas terapêuticas disponíveis no SUS==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Alternativas terapêuticas disponíveis no SUS==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Os seguintes medicamentos (''clique no nome do medicamento para consultar como ter acesso ao mesmo'') '''estão disponíveis no âmbito do SUS pelo&amp;#160; Componente Estratégico da Assistência Farmacêutica (CESAF) para o tratamento da Hepatite C e Coinfecções''' &amp;lt;ref&amp;gt;[https://www.gov.br/saude/pt-br/composicao/sectics/rename RENAME 2024]&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[https://www.gov.br/conitec/pt-br/midias/relatorios/2026/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;relatorio&lt;/del&gt;-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;de-recomendacao&lt;/del&gt;-no-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;1&lt;/del&gt;-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;110&lt;/del&gt;-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;protocolo&lt;/del&gt;-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;clinico&lt;/del&gt;-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;e&lt;/del&gt;-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;diretrizes&lt;/del&gt;-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;terapeuticas-hepatite-c&lt;/del&gt;/@@display-file/file Protocolo Clínico e Diretrizes Terapêuticas Hepatite C e Coinfecções] &amp;lt;/ref&amp;gt;:&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Os seguintes medicamentos (''clique no nome do medicamento para consultar como ter acesso ao mesmo'') '''estão disponíveis no âmbito do SUS pelo&amp;#160; Componente Estratégico da Assistência Farmacêutica (CESAF) para o tratamento da Hepatite C e Coinfecções''' &amp;lt;ref&amp;gt;[https://www.gov.br/saude/pt-br/composicao/sectics/rename RENAME 2024]&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[https://www.gov.br/conitec/pt-br/midias/relatorios&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;/portaria&lt;/ins&gt;/2026/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;portaria&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;sctiems&lt;/ins&gt;-no-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;39&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;de&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;20&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;de&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;julho&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;de&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;2026&lt;/ins&gt;/@@display-file/file Protocolo Clínico e Diretrizes Terapêuticas Hepatite C e Coinfecções] &amp;lt;/ref&amp;gt;:&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[Alfapeguinterferona 2a]] &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[Alfapeguinterferona 2a]] &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=76600&amp;oldid=prev</id>
		<title>Anonimo: Substituição de texto - &quot;[https://www.gov.br/conitec/pt-br/midias/relatorios/2026/relatorio-de-recomendacao-no-1-110-protocolo-clinico-e-diretrizes-terapeuticas-hepatite-c/@@display-file/file Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções]&quot; por &quot;[https://www.gov.br/conitec/pt-br/midias/relatorios/portaria/2026/portaria-sctiems-no-39-de-20-de-julho-de-2026/@@display-file/file Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções]&quot;</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=76600&amp;oldid=prev"/>
				<updated>2026-10-06T20:57:42Z</updated>
		
		<summary type="html">&lt;p&gt;Substituição de texto - &amp;quot;[https://www.gov.br/conitec/pt-br/midias/relatorios/2026/relatorio-de-recomendacao-no-1-110-protocolo-clinico-e-diretrizes-terapeuticas-hepatite-c/@@display-file/file Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções]&amp;quot; por &amp;quot;[https://www.gov.br/conitec/pt-br/midias/relatorios/portaria/2026/portaria-sctiems-no-39-de-20-de-julho-de-2026/@@display-file/file Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções]&amp;quot;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 20h57min de 6 de outubro de 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l25&quot; &gt;Linha 25:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 25:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_2024.pdf Relação Nacional de Medicamentos Essenciais - RENAME 2024]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_2024.pdf Relação Nacional de Medicamentos Essenciais - RENAME 2024]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://www.gov.br/conitec/pt-br/midias/relatorios/portaria/2026/portaria-sctie-ms-no-39-de-20-de-julho-de-2026/@@display-file/file Portaria SCTIE/MS nº 39, de 21 de julho de 2026] - [https://www.gov.br/conitec/pt-br/midias/relatorios/2026/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;relatorio&lt;/del&gt;-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;de-recomendacao&lt;/del&gt;-no-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;1&lt;/del&gt;-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;110&lt;/del&gt;-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;protocolo&lt;/del&gt;-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;clinico&lt;/del&gt;-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;e&lt;/del&gt;-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;diretrizes&lt;/del&gt;-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;terapeuticas-hepatite-c&lt;/del&gt;/@@display-file/file Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://www.gov.br/conitec/pt-br/midias/relatorios/portaria/2026/portaria-sctie-ms-no-39-de-20-de-julho-de-2026/@@display-file/file Portaria SCTIE/MS nº 39, de 21 de julho de 2026] - [https://www.gov.br/conitec/pt-br/midias/relatorios&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;/portaria&lt;/ins&gt;/2026/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;portaria&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;sctiems&lt;/ins&gt;-no-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;39&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;de&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;20&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;de&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;julho&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;de&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;2026&lt;/ins&gt;/@@display-file/file Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Informações sobre o medicamento ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Informações sobre o medicamento ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=76180&amp;oldid=prev</id>
		<title>Anonimo: Substituição de texto - &quot;[https://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_2024.pdf Relação Nacional de Medicamentos Essenciais - RENAME (2024)]&quot; por &quot;[https://www.gov.br/saude/pt-br/composicao/sectics/rename Relação Nacional de Medicamentos Essenciais - RENAME (2024)]&quot;</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=76180&amp;oldid=prev"/>
				<updated>2026-09-28T18:40:34Z</updated>
		
		<summary type="html">&lt;p&gt;Substituição de texto - &amp;quot;[https://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_2024.pdf Relação Nacional de Medicamentos Essenciais - RENAME (2024)]&amp;quot; por &amp;quot;[https://www.gov.br/saude/pt-br/composicao/sectics/rename Relação Nacional de Medicamentos Essenciais - RENAME (2024)]&amp;quot;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 18h40min de 28 de setembro de 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l29&quot; &gt;Linha 29:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 29:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Informações sobre o medicamento ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Informações sobre o medicamento ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;O medicamento '''ribavirina não pertence''' ao elenco da [https://&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;bvsms.saude&lt;/del&gt;.gov.br/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;bvs&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;publicacoes&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;relacao_nacional_medicamentos_2024.pdf &lt;/del&gt;Relação Nacional de Medicamentos Essenciais - RENAME (2024)], que contempla os medicamentos e insumos disponíveis no SUS. Também não se encontra na [http://infosus.saude.sc.gov.br/index.php/Elenco_de_Medicamentos_-_CEAF lista de medicamentos padronizados do Ministério da Saúde], não existindo nenhum protocolo específico para sua liberação pelas Secretarias Estaduais de Saúde.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;O medicamento '''ribavirina não pertence''' ao elenco da [https://&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;www&lt;/ins&gt;.gov.br/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;saude&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;pt-br&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;composicao/sectics/rename &lt;/ins&gt;Relação Nacional de Medicamentos Essenciais - RENAME (2024)], que contempla os medicamentos e insumos disponíveis no SUS. Também não se encontra na [http://infosus.saude.sc.gov.br/index.php/Elenco_de_Medicamentos_-_CEAF lista de medicamentos padronizados do Ministério da Saúde], não existindo nenhum protocolo específico para sua liberação pelas Secretarias Estaduais de Saúde.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Conforme [https://www.saude.sc.gov.br/index.php/pt/legislacao/legislacao-por-assunto/diaf/notas-tecnicas-ceaf-2025 Nota Técnica nº 07/2025 DIAF/SAS/SES/SC, de 19/03/2025], o único fabricante da ribavirina em nível nacional comunicou ao Departamento de HIV/AIDS, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis (DATHI/SVSA/MS), em setembro de 2024, '''a interrupção definitiva da produção e do fornecimento do medicamento ao Ministério da Saúde (MS), haja vista a baixa demanda atual'''. &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Conforme [https://www.saude.sc.gov.br/index.php/pt/legislacao/legislacao-por-assunto/diaf/notas-tecnicas-ceaf-2025 Nota Técnica nº 07/2025 DIAF/SAS/SES/SC, de 19/03/2025], o único fabricante da ribavirina em nível nacional comunicou ao Departamento de HIV/AIDS, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis (DATHI/SVSA/MS), em setembro de 2024, '''a interrupção definitiva da produção e do fornecimento do medicamento ao Ministério da Saúde (MS), haja vista a baixa demanda atual'''. &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=75963&amp;oldid=prev</id>
		<title>Anonimo: Substituição de texto - &quot;https://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_2024.pdf RENAME 2024&quot; por &quot;https://www.gov.br/saude/pt-br/composicao/sectics/rename RENAME 2024&quot;</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=75963&amp;oldid=prev"/>
				<updated>2026-09-28T17:53:31Z</updated>
		
		<summary type="html">&lt;p&gt;Substituição de texto - &amp;quot;https://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_2024.pdf RENAME 2024&amp;quot; por &amp;quot;https://www.gov.br/saude/pt-br/composicao/sectics/rename RENAME 2024&amp;quot;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 17h53min de 28 de setembro de 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l41&quot; &gt;Linha 41:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 41:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Alternativas terapêuticas disponíveis no SUS==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Alternativas terapêuticas disponíveis no SUS==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Os seguintes medicamentos (''clique no nome do medicamento para consultar como ter acesso ao mesmo'') '''estão disponíveis no âmbito do SUS pelo&amp;#160; Componente Estratégico da Assistência Farmacêutica (CESAF) para o tratamento da Hepatite C e Coinfecções''' &amp;lt;ref&amp;gt;[https://&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;bvsms.saude&lt;/del&gt;.gov.br/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;bvs&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;publicacoes&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;relacao_nacional_medicamentos_2024.pdf &lt;/del&gt;RENAME 2024]&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[https://www.gov.br/conitec/pt-br/midias/relatorios/2026/relatorio-de-recomendacao-no-1-110-protocolo-clinico-e-diretrizes-terapeuticas-hepatite-c/@@display-file/file Protocolo Clínico e Diretrizes Terapêuticas Hepatite C e Coinfecções] &amp;lt;/ref&amp;gt;:&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Os seguintes medicamentos (''clique no nome do medicamento para consultar como ter acesso ao mesmo'') '''estão disponíveis no âmbito do SUS pelo&amp;#160; Componente Estratégico da Assistência Farmacêutica (CESAF) para o tratamento da Hepatite C e Coinfecções''' &amp;lt;ref&amp;gt;[https://&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;www&lt;/ins&gt;.gov.br/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;saude&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;pt-br&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;composicao/sectics/rename &lt;/ins&gt;RENAME 2024]&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[https://www.gov.br/conitec/pt-br/midias/relatorios/2026/relatorio-de-recomendacao-no-1-110-protocolo-clinico-e-diretrizes-terapeuticas-hepatite-c/@@display-file/file Protocolo Clínico e Diretrizes Terapêuticas Hepatite C e Coinfecções] &amp;lt;/ref&amp;gt;:&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[Alfapeguinterferona 2a]] &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[Alfapeguinterferona 2a]] &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=74357&amp;oldid=prev</id>
		<title>Anonimo: /* Padronização no SUS */</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=74357&amp;oldid=prev"/>
				<updated>2026-07-30T10:55:13Z</updated>
		
		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Padronização no SUS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 10h55min de 30 de julho de 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l25&quot; &gt;Linha 25:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 25:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_2024.pdf Relação Nacional de Medicamentos Essenciais - RENAME 2024]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_2024.pdf Relação Nacional de Medicamentos Essenciais - RENAME 2024]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://www.gov.br/conitec/pt-br/midias/relatorios/portaria/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;2018&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;portariassctie_82a84_2018.pdf &lt;/del&gt;Portaria SCTIE/MS nº &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;84&lt;/del&gt;, de &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;19 &lt;/del&gt;de &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;dezembro &lt;/del&gt;de &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;2018&lt;/del&gt;] - [https://www.gov.br/conitec/pt-br/midias/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;protocolos&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;pcdt_hepatitec_e_coinfeccoes_2018.pdf &lt;/del&gt;Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://www.gov.br/conitec/pt-br/midias/relatorios/portaria/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;2026&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;portaria-sctie-ms-no-39-de-20-de-julho-de-2026/@@display-file/file &lt;/ins&gt;Portaria SCTIE/MS nº &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;39&lt;/ins&gt;, de &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;21 &lt;/ins&gt;de &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;julho &lt;/ins&gt;de &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;2026&lt;/ins&gt;] - [https://www.gov.br/conitec/pt-br/midias/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;relatorios&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;2026/relatorio-de-recomendacao-no-1-110-protocolo-clinico-e-diretrizes-terapeuticas-hepatite-c/@@display-file/file &lt;/ins&gt;Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Informações sobre o medicamento ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Informações sobre o medicamento ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=74346&amp;oldid=prev</id>
		<title>Anonimo: /* Alternativas terapêuticas disponíveis no SUS */</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=74346&amp;oldid=prev"/>
				<updated>2026-07-30T10:48:17Z</updated>
		
		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Alternativas terapêuticas disponíveis no SUS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 10h48min de 30 de julho de 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l41&quot; &gt;Linha 41:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 41:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Alternativas terapêuticas disponíveis no SUS==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Alternativas terapêuticas disponíveis no SUS==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Os seguintes medicamentos (''clique no nome do medicamento para consultar como ter acesso ao mesmo'') '''estão disponíveis no âmbito do SUS pelo&amp;#160; Componente Estratégico da Assistência Farmacêutica (CESAF) para o tratamento da &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;hepatite &lt;/del&gt;C e &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;coinfecções&lt;/del&gt;''' &amp;lt;ref&amp;gt;[https://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_2024.pdf RENAME 2024]&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[https://www.gov.br/conitec/pt-br/midias/relatorios/2026/relatorio-de-recomendacao-no-1-110-protocolo-clinico-e-diretrizes-terapeuticas-hepatite-c/@@display-file/file Protocolo Clínico e Diretrizes Terapêuticas Hepatite C e Coinfecções] &amp;lt;/ref&amp;gt;:&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Os seguintes medicamentos (''clique no nome do medicamento para consultar como ter acesso ao mesmo'') '''estão disponíveis no âmbito do SUS pelo&amp;#160; Componente Estratégico da Assistência Farmacêutica (CESAF) para o tratamento da &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;Hepatite &lt;/ins&gt;C e &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;Coinfecções&lt;/ins&gt;''' &amp;lt;ref&amp;gt;[https://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_2024.pdf RENAME 2024]&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[https://www.gov.br/conitec/pt-br/midias/relatorios/2026/relatorio-de-recomendacao-no-1-110-protocolo-clinico-e-diretrizes-terapeuticas-hepatite-c/@@display-file/file Protocolo Clínico e Diretrizes Terapêuticas Hepatite C e Coinfecções] &amp;lt;/ref&amp;gt;:&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[Alfapeguinterferona 2a]] &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[Alfapeguinterferona 2a]] &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=74339&amp;oldid=prev</id>
		<title>Anonimo: Substituição de texto - &quot;https://www.gov.br/conitec/pt-br/midias/protocolos/pcdt_hepatitec_e_coinfeccoes_2018.pdf Protocolo Clínico e Diretrizes Terapêuticas Hepatite C e coinfecções&quot; por &quot;https://www.gov.br/conitec/pt-br/midias/relatorios/2026/relatorio-de-recomendacao-no-1-110-protocolo-clinico-e-diretrizes-terapeuticas-hepatite-c/@@display-file/file Protocolo Clínico e Diretrizes Terapêuticas Hepatite C e Coinfecções&quot;</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=74339&amp;oldid=prev"/>
				<updated>2026-07-30T10:44:52Z</updated>
		
		<summary type="html">&lt;p&gt;Substituição de texto - &amp;quot;https://www.gov.br/conitec/pt-br/midias/protocolos/pcdt_hepatitec_e_coinfeccoes_2018.pdf Protocolo Clínico e Diretrizes Terapêuticas Hepatite C e coinfecções&amp;quot; por &amp;quot;https://www.gov.br/conitec/pt-br/midias/relatorios/2026/relatorio-de-recomendacao-no-1-110-protocolo-clinico-e-diretrizes-terapeuticas-hepatite-c/@@display-file/file Protocolo Clínico e Diretrizes Terapêuticas Hepatite C e Coinfecções&amp;quot;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 10h44min de 30 de julho de 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l41&quot; &gt;Linha 41:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 41:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Alternativas terapêuticas disponíveis no SUS==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Alternativas terapêuticas disponíveis no SUS==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Os seguintes medicamentos (''clique no nome do medicamento para consultar como ter acesso ao mesmo'') '''estão disponíveis no âmbito do SUS pelo&amp;#160; Componente Estratégico da Assistência Farmacêutica (CESAF) para o tratamento da hepatite C e coinfecções''' &amp;lt;ref&amp;gt;[https://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_2024.pdf RENAME 2024]&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[https://www.gov.br/conitec/pt-br/midias/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;protocolos&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;pcdt_hepatitec_e_coinfeccoes_2018.pdf &lt;/del&gt;Protocolo Clínico e Diretrizes Terapêuticas Hepatite C e &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;coinfecções&lt;/del&gt;] &amp;lt;/ref&amp;gt;:&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Os seguintes medicamentos (''clique no nome do medicamento para consultar como ter acesso ao mesmo'') '''estão disponíveis no âmbito do SUS pelo&amp;#160; Componente Estratégico da Assistência Farmacêutica (CESAF) para o tratamento da hepatite C e coinfecções''' &amp;lt;ref&amp;gt;[https://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_2024.pdf RENAME 2024]&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[https://www.gov.br/conitec/pt-br/midias/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;relatorios&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;2026/relatorio-de-recomendacao-no-1-110-protocolo-clinico-e-diretrizes-terapeuticas-hepatite-c/@@display-file/file &lt;/ins&gt;Protocolo Clínico e Diretrizes Terapêuticas Hepatite C e &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;Coinfecções&lt;/ins&gt;] &amp;lt;/ref&amp;gt;:&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[Alfapeguinterferona 2a]] &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[Alfapeguinterferona 2a]] &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=73258&amp;oldid=prev</id>
		<title>Anonimo em 20h01min de 27 de março de 2026</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=73258&amp;oldid=prev"/>
				<updated>2026-03-27T20:01:13Z</updated>
		
		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 20h01min de 27 de março de 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot; &gt;Linha 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;font-size:small;color:blue&amp;quot;&amp;gt; Medicamento Sujeito a Controle Especial - Este medicamento pertence à '''lista C1''' da Portaria nº 344, de 12 de maio de 1998 &amp;lt;ref&amp;gt;[https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/lista-substancias Portaria n.344, de 12 de maio de 1998] &amp;lt;/ref&amp;gt;.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;font-size:small;color:blue&amp;quot;&amp;gt; &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;'''&lt;/ins&gt;Medicamento Sujeito a Controle Especial&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;''' &lt;/ins&gt;- Este medicamento pertence à '''lista C1''' da Portaria nº 344, de 12 de maio de 1998 &amp;lt;ref&amp;gt;[https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/lista-substancias Portaria n.344, de 12 de maio de 1998] &amp;lt;/ref&amp;gt;. &amp;lt;span style=&amp;quot;font-size:small;color:blue&amp;quot;&amp;gt;&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;'''&lt;/ins&gt;Validade da receita:&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;''' &lt;/ins&gt;30 dias&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;. &lt;/ins&gt;&amp;lt;span style=&amp;quot;font-size:small;color:blue&amp;quot;&amp;gt;&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;'''&lt;/ins&gt;Prescrição máxima:&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;''' &lt;/ins&gt;quantidade para o tratamento correspondente a no máximo 60 dias&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;. &lt;/ins&gt;&amp;lt;span style=&amp;quot;font-size:small;color:blue&amp;quot;&amp;gt; Para informações complementares consulte o item [[Prescrições Médicas]] na página principal.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;font-size:small;color:blue&amp;quot;&amp;gt;Validade da receita: 30 dias&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;font-size:small;color:blue&amp;quot;&amp;gt;Prescrição máxima: quantidade para o tratamento correspondente a no máximo 60 dias &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;font-size:small;color:blue&amp;quot;&amp;gt; Para informações complementares consulte o item [[Prescrições Médicas]] na página principal&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;As substâncias presentes na Portaria nº 344/98 necessitam de controle mais rigoroso uma vez que apresentam ação no sistema nervoso central com capacidade de causar dependência física ou psíquica; assim como podem ser abortivas ou altamente teratogênicas. Além disso, em alguns casos são utilizadas para fabricação de entorpecentes e psicotrópicos ou são classificadas como substâncias anabolizantes&lt;/del&gt;. &amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Registro na Anvisa ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Registro na Anvisa ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=73135&amp;oldid=prev</id>
		<title>Anonimo: Substituição de texto - &quot;[https://www.cff.org.br/userfiles/file/portarias/344.pdf Portaria n.344, de 12 de maio de 1998]&quot; por &quot;[https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/lista-substancias Portaria n.344, de 12 de maio de 1998]&quot;</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=73135&amp;oldid=prev"/>
				<updated>2026-03-27T18:51:47Z</updated>
		
		<summary type="html">&lt;p&gt;Substituição de texto - &amp;quot;[https://www.cff.org.br/userfiles/file/portarias/344.pdf Portaria n.344, de 12 de maio de 1998]&amp;quot; por &amp;quot;[https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/lista-substancias Portaria n.344, de 12 de maio de 1998]&amp;quot;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 18h51min de 27 de março de 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot; &gt;Linha 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;font-size:small;color:blue&amp;quot;&amp;gt; Medicamento Sujeito a Controle Especial - Este medicamento pertence à '''lista C1''' da Portaria nº 344, de 12 de maio de 1998 &amp;lt;ref&amp;gt;[https://www.&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;cff.org&lt;/del&gt;.br/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;userfiles&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;file&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;portarias&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;344.pdf &lt;/del&gt;Portaria n.344, de 12 de maio de 1998] &amp;lt;/ref&amp;gt;.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;font-size:small;color:blue&amp;quot;&amp;gt; Medicamento Sujeito a Controle Especial - Este medicamento pertence à '''lista C1''' da Portaria nº 344, de 12 de maio de 1998 &amp;lt;ref&amp;gt;[https://www.&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;gov&lt;/ins&gt;.br/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;anvisa/pt-br/assuntos&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;medicamentos&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;controlados&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;lista-substancias &lt;/ins&gt;Portaria n.344, de 12 de maio de 1998] &amp;lt;/ref&amp;gt;.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;font-size:small;color:blue&amp;quot;&amp;gt;Validade da receita: 30 dias&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;font-size:small;color:blue&amp;quot;&amp;gt;Validade da receita: 30 dias&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	<entry>
		<id>http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=71801&amp;oldid=prev</id>
		<title>Anonimo: /* Informações sobre o financiamento do medicamento */</title>
		<link rel="alternate" type="text/html" href="http://infosus.saude.sc.gov.br/index.php?title=Ribavirina&amp;diff=71801&amp;oldid=prev"/>
				<updated>2026-02-11T18:01:46Z</updated>
		
		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Informações sobre o financiamento do medicamento&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;tr style='vertical-align: top;' lang='pt-BR'&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Edição anterior&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Edição das 18h01min de 11 de fevereiro de 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l69&quot; &gt;Linha 69:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linha 69:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Informações sobre o financiamento do medicamento==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Informações sobre o financiamento do medicamento==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;O medicamento '''ribavirina''' pertence ao Componente Estratégico da Assistência Farmacêutica (CESAF), '''sendo sua aquisição de responsabilidade exclusiva da União'''. O Ministério da Saúde adquire e distribui o medicamento aos Estados e ao Distrito Federal, cabendo a esses o recebimento, o armazenamento e a distribuição aos municípios&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;O medicamento '''ribavirina''' pertence ao Componente Estratégico da Assistência Farmacêutica (CESAF), '''sendo sua aquisição de responsabilidade exclusiva da União'''. O Ministério da Saúde adquire e distribui o medicamento aos Estados e ao Distrito Federal, cabendo a esses o recebimento, o armazenamento e a distribuição aos municípios&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Referências==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Referências==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Anonimo</name></author>	</entry>

	</feed>